The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

NCT05075512 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm Female

Interventions

DRUG: anlotinib, fulvestrant

Sponsor

Zhejiang Cancer Hospital